PharmacoEconomics & Outcomes News 792, p26 - 2 Dec 2017 Rotavirus vaccine potentially cost effective in Afghanistan Introduction of a rotavirus vaccination programme is likely to be cost effective in Afghanistan, according to findings of a study published in Vaccine. The ProVac Initiative UNIVAC model was used to evaluate the potential impact and cost effectiveness of a national rotavirus immunization programme with a two- dose schedule of Rotarix (RIX 4414) in ten birth cohorts in Afghanistan between 2017 and 2026, compared with no rotavirus vaccination, from government and societal perspectives, with and without Gavi (Vaccine Alliance) support. The assumed vaccine price was $2.02 per dose. Over the 10-year period, rotavirus vaccination was predicted to avert over one million cases of rotavirus infection, and approximately 660 000 outpatient visits, 50 000 rotavirus-related hospital admissions, 650 000 disability-adjusted life-years (DALYs) and 12 000 deaths. It would save $1.35 million in treatment costs from the government perspective and $2.80 million from a societal perspective. Without the Gavi subsidy, the estimated incremental cost-effectiveness ratio (ICER) for rotavirus vaccination versus no vaccination was $82 per DALY averted from the government perspective and $80 per DALY averted from the societal perspective. With the Gavi subsidy, ICERs were $31 and $29 per DALY averted, respectively. It was estimated that the annual cost of the rotavirus vaccination programme would account for 2.8% of the total immunisation budget and 0.1% of total health expenditure in Afghanistan in 2017. "In summary, this analysis demonstrates that rotavirus vaccination is likely to be highly cost-effective and avert a substantial health and economic burden of disease in Afghanistan," said the authors. * 2017 US dollars Anwari P, et al. Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan. Vaccine : 26 Oct 2017. Available from: URL: http://doi.org/10.1016/ j.vaccine.2017.10.058 803284215 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792
PharmacoEconomics & Outcomes News – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud